A novel GABA A alpha 5 receptor inhibitor with therapeutic potential
Envoyer une demande de publication
close

Demande de publication

Merci pour votre intérêt pour nos produits et votre demande concernant cette publication, qui vous sera envoyée si le chercheur et le journal l'autorisent. Notre équipe commerciale vous contactera rapidement.



- Catégories : Domaines de recherche divers , Publications - ID: 763

Authors
Ling I, Mihalik B, Etherington LA, Kapus G, Pálvölgyi A, Gigler G et al.


Lab
Chemical Research Division, Egis Pharmaceuticals PLC, Budapest, Hungary.

Journal
Eur J Pharmacol.

Abstract
Novel 2,3-benzodiazepine and related isoquinoline derivatives, substituted at position 1 with a 2-benzothiophenyl moiety, were synthesized to produce compounds that potently inhibited the action of GABA on heterologously expressed GABAA receptors containing the alpha 5 subunit (GABAA ?5), with no apparent affinity for the benzodiazepine site. Substitutions of the benzothiophene moiety at position 4 led to compounds with drug-like properties that were putative inhibitors of extra-synaptic GABAA ?5 receptors and had substantial blood-brain barrier permeability. Initial characterization in vivo showed that 8-methyl-5-[4-(trifluoromethyl)-1-benzothiophen-2-yl]-1,9-dihydro-2H-[1,3]oxazolo[4,5-h][2,3]benzodiazepin-2-one was devoid of sedative, pro-convulsive or motor side-effects, and enhanced the performance of rats in the object recognition test. In summary, we have discovered a first-in-class GABA-site inhibitor of extra-synaptic GABAA ?5 receptors that has promising drug-like properties and warrants further development.

BIOSEB Instruments Used:
LabScribe 2.0 (LS-20)

Produits associés

Partager ce contenu